PR
    Pharmacy Remedy

    Immunotherapy (Checkpoint Inhibitors)

    Imfinzi (durvalumab) in Saudi Arabia — Regulatory and Supply Information

    Anti-PD-L1 antibody indicated for unresectable stage III NSCLC after chemoradiation (PACIFIC), extensive-stage SCLC (with etoposide + platinum), biliary tract cancer (TOPAZ-1) and hepatocellular carcinoma (HIMALAYA, with tremelimumab). Dosed 1500 mg q4w or 10 mg/kg q2w.

    Imfinzi (durvalumab) original manufacturer carton

    Prescription-only medicine. No pricing is published on this page. Prescription-medicine pricing is not advertised to the public in this market.

    This page is informational and is not an advertisement, a promotional communication, or medical advice. It does not offer any medicine for sale to the public. Treatment decisions belong to your treating physician.

    What this medicine is

    Active ingredient
    durvalumab
    Marketing authorisation holder
    AstraZeneca
    Therapeutic class
    Immunotherapy (Checkpoint Inhibitors)

    Presentations and dosage forms

    • 120 mg / 2.4 mL vial
    • 500 mg / 10 mL vial (IV infusion)

    Storage, cold chain and handling

    Refrigerate 2–8°C, protect from light, do not freeze or shake.

    The regulatory route in Saudi Arabia

    Medicines in Saudi Arabia are regulated by the Saudi Food and Drug Authority (SFDA). Every product described on this site is a prescription-only medicine, supplied against a valid prescription from a treating physician and dispensed through licensed channels. Nothing on this page is an offer to sell to the public.

    Controlled medicines carried by travellers run through the SFDA's Controlled Drugs System (CDS) at cds.sfda.gov.sa. The SFDA published its Guideline for Clearance Permit of Controlled Drugs for Travelers on 14 August 2025, which sets out the electronic clearance request process.

    Saudi Arabia updated its personal-import and prescription rules in December 2024. Confirm the current requirements directly with the SFDA before applying.

    The SFDA publishes registration data for locally manufactured and non-local human medicines as open data. It does not publish a medicine price dataset, so any site presenting an "official SFDA price" for a specific product is not drawing on a published SFDA source. The SFDA also publishes drug circulars, withdrawal notices and current shortage information in Arabic — worth checking first, because a national shortage is the most common reason a prescribed medicine cannot be dispensed locally.

    The process, step by step

    1. Create an account on the Controlled Drugs System (CDS) at cds.sfda.gov.sa.
    2. Submit an electronic clearance request containing the patient details and the trip details.
    3. Upload the prescription, the medical report and proof of identity.
    4. Specify the trade name, active ingredient, concentration and quantity of each medicine.
    5. Track the request status, which is shown as Submitted, Completed, Rejected or Incomplete.

    Documentation typically required

    • A valid prescription from the treating physician, naming the trade name, active ingredient, concentration and quantity
    • A medical report describing the diagnosis and the treatment plan
    • Proof of identity for the patient (and for the accompanying person, where relevant)
    • Travel details, where the medicine is being carried by a traveller
    • For a hospital or clinic: the establishment licence and the request of the responsible pharmacist

    Official sources

    Why the same medicine is priced differently in Türkiye

    This is how the Turkish pricing system works. These are published facts about a state mechanism, not a claim about what we charge.

    • Turkish medicine prices are calculated from a fixed pharmaceutical euro rate rather than the spot exchange rate. Under Decision No. 11031 (Resmî Gazete 33194, 12 March 2026) that rate is set at 65% of the previous year's average Turkish Central Bank euro selling rate.
    • The reference price is derived from the lowest ex-factory price in a basket of five to ten EU member states designated by the Ministry of Health.
    • A mandatory public discount of roughly 28–41% is then applied, depending on the product category and price band. The band thresholds change with each SUT revision, so we do not reproduce them here.

    Official published lists — our figures appear nowhere

    We publish no price. Each authority below publishes its own list. Read them directly:

    Compare them yourself.

    For international context: RAND Corporation, analysing 2022 data and publishing in February 2024, found US prices were 278% of prices in 33 other high-income countries, rising to 422% for brand-name originator medicines.

    How to obtain a price

    We do not publish prices. The price depends on the dose, the number of vials and the number of treatment cycles. Send your prescription and medical report and you will receive a written quote within 24 hours.

    Sourced through Türkiye pharmacy channels · İTS serial-traceable — every Turkish pack carries an İTS karekod encoding the GTIN, serial number, batch and expiry, which can be checked against Türkiye's Pharmaceutical Track and Trace System.

    How to obtain a price

    Search terms for this medicine

    The same molecule is searched under several names. All of the following refer to the same product:

    • Imfinzi
    • durvalumab
    • إمفينزي
    • دورفالوماب
    • Imfinzi Saudi Arabia
    • إمفينزي المملكة العربية السعودية
    • durvalumab SFDA
    • Imfinzi prescription
    • إمفينزي وصفة طبية

    Frequently asked questions

    Prescription-based enquiry

    If you hold a valid prescription from a treating physician in Saudi Arabia, you can send us the prescription details and we will reply with the regulatory and documentation position for that specific product. We do not publish pricing for Saudi Arabia and we do not sell to the public.

    Send a prescription-based enquiry

    Background reading

    Related medicines

    Medically reviewed by Pharmacy Remedy Pharmacovigilance & Compliance Desk · Last updated: 2026-07-29 · Saudi Food and Drug Authority

    For healthcare professionals

    Prescribers, hospital and specialty pharmacies, oncology centres and procurement departments: named patient supply, documentation and the sourcing workflow.